Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vir Biotechnology, Inc.

NASDAQ: VIR · Life Sciences · 9 alerts · CIK 1706431

Vir Biotechnology, Inc. stories on ALFA USA NewsRead the news →
Share price
$9.58Close, Nov 16
Market cap
$1.64B
Shares outstanding
171.27MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vir Biotechnology, Inc. filings on SEC EDGAR ↗

8:31 AM ET 8-K
Clinical Trial Data

Vir Biotechnology Clinical Trial Data

Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.